Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus

Pest Management Science

Volumn 69, Issue 2, 2013, Pages 165-170

  Verweij, Paul E ^a   Kema, Gert H J ^b   Zwaan, Bas ^b   Melchers, Willem JG ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Aspergillosis; Aspergillus fumigatus; Demethylase inhibitors; Resistance; Triazoles

Indexed keywords

ANTIFUNGAL AGENT; FUNGICIDE; TRIAZOLE DERIVATIVE;

CHEMICAL CONTROL; ENZYME ACTIVITY; FUNGAL DISEASE; FUNGICIDE; INHIBITOR; PESTICIDE RESISTANCE;

ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG EFFECT; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG RESISTANCE, FUNGAL; FUNGICIDES, INDUSTRIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; TRIAZOLES;

ASPERGILLUS; ASPERGILLUS FUMIGATUS;

EID: 84872766561     PISSN: 1526498X     EISSN: 15264998     Source Type: Journal    
DOI: 10.1002/ps.3390     Document Type: Article

References (37)

1. Latgé JP, Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12: 310-350 (1999).
2. Pagano L, Caira M, Picardi M, Candoni A, Melillo L, Fianchi L, et al, Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality-SEIFEM-C report. Clin Infect Dis 44: 1524-1525 (2007).
3. Lass-Flörl C, The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52: 197-205 (2009).
4. Patterson JE, Zidouh A, Miniter P, Andriole VT and Patterson TF, Hospital epidemiologic surveillance for invasive aspergillosis: patient demographics and the utility of antigen detection. Infect Control Hosp Epidemiol 18: 104-108 (1997).
5. Sarfati J, Monod M, Recco P, Sulahian A, Pinel C, Candolfi E, et al, Recombinant antigens as diagnostic markers for aspergillosis. Diagn Microbiol Infect Dis 55: 279-291 (2006).
6. Einsele H, Quabeck K, Müller KD, Hebart H, Rothenhöfer I, Löffler J, et al, Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation. Lancet 352: 1443 (1998).
7. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46: 327-360 (2008).
8. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al, Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348-359 (2007).
9. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356: 335-347 (2007).
10. Verweij PE, Mellado E and Melchers W, Multiple-triazole-resistant aspergillosis. N Engl J Med 356: 1481-1483 (2007).
11. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al, Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5: e219 (2008).
12. Verweij PE, Te Dorsthorst DT, Rijs AJ, De Vries-Hospers HG and Meis JF, Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 40: 2648-2650 (2002).
13. van der Linden JWM, Snelders E, Kampinga GA, Rijnders B, Mattsson E, Debets-Ossenkopp YJ, et al, Clinical implications of azole-resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg Infect Dis 17: 1846-1854 (2011).
14. Verweij PE, Howard SJ, Melchers WJ and Denning DW, Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 12: 141-147 (2009).
15. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE and Mouton JW, Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 54: 4758-4764 (2010).
16. Mavridou E, Brüggemann RJ, Melchers WJ, Mouton JW and Verweij PE, Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 54: 865-865 (2010).
17. van der Linden JW, Snelders E, Arends JP, Daenen SM, Melchers WJ and Verweij PE, Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. J Clin Microbiol 48: 1478-1480 (2010).
18. Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, Gore R, et al, High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 52: 1123-1129 (2011).
19. Chen J, Li H, Li R, Bu D and Wan Z, Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother 55: 31-37 (2005).
20. Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, et al, Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 56: 10-16 (2012).
21. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, et al, Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15: 1068-1076 (2009).
22. Snelders E, Camps SMT, Karawajczyk A, Schaftenaar G, Kema GHJ, van der Lee HAL, et al, Triazole fungicides can induce cross-resistance to medical triazole in Aspergillus fumigatus. PLoS One 7: e31801 (2012).
23. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, et al, A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 51: 1897-1904 (2007).
24. Snelders E, Huis In't Veld RA, Rijs AJ, Kema GH, Melchers WJ and Verweij PE, Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 75: 4053-4057 (2009).
25. Verweij PE, Melchers WJG and Kema GHJ, Azole resistance in Aspergillus fumigatus: collateral damage of fungicide use? Modern Fungicides and Antifungal Compounds VI. Proceedings of the 16th International Reinhardsbrunn Symposium, 25-29 April 2010, Friedrichroda, Germany, pp. 301-306 (2011).
26. Kwon-Chung KJ and Bennett JE, Aspergillosis, in Medical Mycology. Lea & Febiger, Philadelphia, PA, pp. 201-247 (1992).
27. Verweij PE, Snelders E, Kema GH, Mellado E and Melchers WJ, Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 9: 789-795 (2009).
28. Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE and Pajkrt D, Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol 47: 217-220 (2009).
29. Verweij PE, van der Linden JWM, Camps SMT and Melchers WJG, A new resistance mechanism of environmental origin conferring voriconazole resistance has emerged in clinical Aspergillus fumigatus isolates in the Netherlands. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, abstract M-624 (2010).
30. Arendrup MC, Mavridou E, Mortensen KL, Snelders E, Frimodt-Møller N, Khan H, et al, Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS ONE 5: e10080 (2010).
31. Camps SMT, Dutilh BE, Arendrup MC, Rijs AJMM, Snelders E, Huynen MA, et al, Discovery of a new azole resistance mechanism in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One accepted (2012).
32. th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, abstract O345 (2010).
33. Kelly SL, Lamb DC and Kelly DE, Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett 180: 171-175 (1999).
34. Alcazar-Fuoli L, Mellado E, Garcia-Effron G, Lopez JF, Grimalt JO, Cuenca-Estrella JM, et al, Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids 73: 339-347 (2008).
35. van der Linden JWM, Arendrup MC and Verweij PE, Prospective international surveillance of azole resistance in Aspergillus fumigatus (SCARE-Network). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, abstract M-490 (2011).
36. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ and Balajee SA, Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 55: 4465-4468 (2011).
37. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH and Meis JF, Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 67: 362-366 (2011).